CD12 filled up in the time it would take to even get the data together to begin a 75% analysis.. what is the point when the trial's already fully enrolled? No insights would have been gleaned in time to balance out all the issues with misdistribution of age and severity.

That those imblanances existed is the largest part of the problem. That deserves consequences.